Want to see HK:1863 full AI Analyst Report?
Top Page
China Longevity Group Co. Ltd.
(1863)
Select Model
Select Model
Rating:50Neutral
Price Target:―
Action:Reiterated
Date:10/01/26
The score is held back primarily by weaker financial performance: margin/return deterioration since the 2021 peak, higher leverage, and inconsistent cash generation with volatile and often negative free cash flow. Valuation is a partial offset with a moderate P/E, but limited supporting data (no dividend yield and no technical/earnings-call inputs) keeps the overall score near the middle of the range.
Positive Factors
Positive Revenue Growth
Reported revenue growth indicates the company continues to expand its top line, providing a foundation for future operating leverage and reinvestment. Although recent annual revenue has been volatile, the positive growth measure remains a constructive indicator of ongoing business activity.
Negative Factors
Margin and Profit Compression
Deteriorating margins and lower operating profit indicate reduced earnings quality and weaker operating leverage. The trend may limit the company’s ability to convert revenue growth into durable profit expansion, while also reducing internal funds available for investment and balance-sheet improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Revenue Growth
Reported revenue growth indicates the company continues to expand its top line, providing a foundation for future operating leverage and reinvestment. Although recent annual revenue has been volatile, the positive growth measure remains a constructive indicator of ongoing business activity.
Read all positive factors
China Longevity Group Co. Ltd. (1863) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
N/A
Dividend Yield5.03%
Average Volume (3M)N/A
Price to Earnings (P/E)22.9
Beta (1Y)N/A
Revenue Growth6.49%
EPS Growth-5.55%
CountryHK
EmployeesN/A
SectorGeneral
Sector StrengthN/A
IndustryIndustrial Materials
Share Statistics
EPS (TTM)0.05
Shares Outstanding852,612,500
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)1.32
Price to Sales (P/S)0.89
P/FCF Ratio565.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Longevity Group Co. Ltd. Business Overview & Revenue Model
Company Description
China Longevity Group operates within the reinforced materials industry, engaging comprehensively in the design, development, production, and distribution of its specialized products. These offerings include advanced polymer-processed polyester fa...
China Longevity Group Co. Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
49
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.17B | 1.17B | 933.93M | 926.62M | 1.44B |
| Gross Profit | 203.90M | 202.74M | 186.04M | 146.32M | 260.47M |
| EBITDA | 106.46M | 127.29M | 127.75M | 118.23M | 191.28M |
| Net Income | 43.19M | 55.55M | 63.00M | 46.19M | 106.93M |
Balance Sheet | |||||
| Total Assets | 1.98B | 1.94B | 1.71B | 1.33B | 1.39B |
| Cash, Cash Equivalents and Short-Term Investments | 178.41M | 83.35M | 64.36M | 90.58M | 77.99M |
| Total Debt | 724.45M | 680.75M | 619.57M | 332.50M | 255.45M |
| Total Liabilities | 1.11B | 1.11B | 951.79M | 688.27M | 831.66M |
| Stockholders Equity | 797.67M | 749.28M | 676.42M | 599.34M | 531.17M |
Cash Flow | |||||
| Free Cash Flow | 1.85M | -23.86M | -354.53M | -138.53M | 55.80M |
| Operating Cash Flow | 108.71M | 103.56M | -10.62M | 35.14M | 177.51M |
| Investing Cash Flow | -104.77M | -135.18M | -333.16M | -95.10M | -201.75M |
| Financing Cash Flow | 42.15M | 50.22M | 317.36M | 73.07M | 67.21M |
China Longevity Group Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.53B | 8.19 | 43.78% | 12.48% | -14.68% | -13.60% | |
67 Neutral | HK$324.38M | -4.20 | -10.76% | 7.90% | -1.37% | -340.31% | |
56 Neutral | HK$1.10B | 77.62 | 0.48% | 1.10% | -3.26% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ― | 22.90 | 5.57% | 5.03% | 6.49% | -5.55% | |
50 Neutral | HK$467.79M | -144.57 | -0.41% | ― | 3.16% | -101.02% | |
49 Neutral | HK$663.72M | -1.62 | -25.36% | 1.47% | -8.94% | -140.82% |
* General Sector Average
HK:1863
China Longevity Group Co. Ltd.
―
―
―
HK:1830
Perfect Medical Health Management Limited
1.17
-0.19
-14.21%
HK:2138
EC Healthcare
0.55
-0.17
-23.61%
HK:3869
Hospital Corporation of China Ltd
3.39
-3.37
-49.85%
HK:3886
Town Health International Medical Group Ltd.
0.16
-0.12
-43.21%
HK:0722
UMP Healthcare Holdings Limited
0.41
-0.04
-9.40%
China Longevity Group Co. Ltd. Corporate Events
China Longevity Group Lifts Interim Profit Despite Margin Pressure
Aug 31, 2026
China Longevity Group reported interim revenue of about RMB646.1 million for the six months ended 30 June 2026, a year-on-year increase of 9.2%, though its gross profit margin slipped from 17.0% to 15.6%, reflecting pressure on margins despite hig...
China Longevity Group Sets Board Meeting to Review Interim Results and Dividend
Aug 6, 2026
China Longevity Group Company Limited has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the potential declaration and payment of an interi...
China Longevity Group Still Healthy but Faces Prolonged Trading Suspension Review
Jul 31, 2026
China Longevity Group Company Limited, a Cayman Islands-incorporated issuer listed in Hong Kong under stock code 1863, operates a group structure engaged in production and materials-related activities. The company highlights research and developme...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.